German National Genome Research Network to Analyze More Than 17,000 DNA Samples Using Affymetrix Technology
Affymetrix Inc. (Nasdaq:AFFX) today announced that the National Genome Research Network (NGFN) in Germany has selected the Affymetrix Genome-Wide Human SNP Array 5.0 to genotype more than 17,000 individuals. Access to this detailed genetic information should help researchers better understand the underlying causes and develop more effective treatments for 25 complex diseases, including Alzheimer’s, epilepsy, heart diseases, malaria and Parkinson’s. The NGFN will use the new SNP Array 6.0 when it becomes available later this year.
The project is part of one of the world’s largest genetic research efforts. The NGFN consists of a team of scientists from more than 10 research institutions around the country who are committed to standardizing the set of controls, protocols and analysis tools for whole-genome association studies. Results of the studies will flow into a database accessible to both researchers from academia and the pharmaceutical industry.
“With this large-scale project, we hope to encourage the launch of further projects of this kind,” said Professor Stefan Schreiber of the University of Kiel. “Our aim is to discover how similar diseases are linked in order to identify genes related to multiple diseases. In near time, the global community will have the chance of a joint analysis across countries using multiple association samples. The ability to analyze large sample cohorts such as these with cutting-edge technologies is crucial to understanding complex genetics.”
The latest NGFN project builds on the success of the first project, which focused on developing a control cohort database that would be free and available to the public. The database is enabling researchers from both academia and the pharmaceutical industry to reduce the number of required control samples and increase the genetic power of their current studies by adding age- and sex-matched controls from similar ethnic backgrounds as their cases. As a result of this project and others around the world, the Affymetrix Control Program is now the world’s largest population genetics resource, containing genotype data from more than 12,000 samples.
The Affymetrix SNP Array 5.0 was developed to help researchers better identify and understand the genetic variations associated with complex diseases, such as autism, bipolar disease, cancer, diabetes and heart disease. The SNP Array 5.0 features single nucleotide polymorphisms (SNPs) from the original Affymetrix two-chip 500K Array Set, as well as 420,000 additional probes that can measure other genetic differences, such as copy number variation. The SNP Array 5.0 gives researchers a significant increase in information above the original 500K Array Set for the same price, while reducing the array processing time. The NGFN will also have access to the next-generation SNP Array 6.0, which is expected to be available later this year.
“The latest studies for the National Genome Research Network are great examples of experiments that are now possible to perform because of the latest innovative Affymetrix genotyping products,” said Kevin King, president of life sciences business and executive vice president at Affymetrix. “Because of the advances in technology and the creation of the Affymetrix Control Program, Affymetrix genotyping products are considered to be the gold standard in large-scale genotyping, enabling researchers to accelerate discoveries in the lab and help bring new treatments and tests to the patient’s bedside.”
About the National Genome Research Network
The National Genome Research Network (NGFN) is a large-scale biomedical program initiated by the German Federal Ministry for Education and Research (BMBF). The research activity of the NGFN focuses on investigating genetic causes of common diseases. To accomplish this, a unique organizational structure has been created so that leading experts from both systematic genome research and clinical research can collaborate closely. Together, they seek to understand the complex control mechanisms of the human body at the DNA, RNA and protein level in order to find keys to new treatments for currently incurable diseases. For more information about the NGFN, please visit the NGFN website at www.ngfn.de.
About Affymetrix
Affymetrix GeneChip® microarray technology is the industry-standard tool for analyzing complex genetic information. After inventing microarray technology in the late 1980s, Affymetrix scientists have been dedicated to developing innovative products that provide researchers with a more complete view of the genome. These products continue to accelerate genetic research and enable scientists to develop diagnostics and tailor treatments for individual patients by identifying and measuring the genetic information associated with complex diseases.
Today, Affymetrix technology is used by the world’s top pharmaceutical, diagnostic and biotechnology companies, as well as leading academic, government and not-for-profit research institutes. More than 1,500 systems have been shipped around the world and more than 8,500 peer-reviewed papers have been published using the technology.
Affymetrix is headquartered in Santa Clara, Calif., and has manufacturing facilities in Sacramento, Calif., and Singapore. The company has about 1,100 employees worldwide and maintains sales and distribution operations across Europe and Asia. For more information about Affymetrix, please visit the company’s website at www.affymetrix.com.
Forward-looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix’ “expectations,”"beliefs,”"hopes,”"intentions,”"strategies” or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the agreement with the National Genome Research Network discussed in this press release; risks of the company’s ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses; uncertainties relating to technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation. These and other risk factors are discussed in Affymetrix’ Form 10-K for the year ended December 31, 2006, and other SEC reports, including its Quarterly Reports on Form 10-Q for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix’ expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
NOTE: Affymetrix, the Affymetrix logo and GeneChip® are registered trademarks owned or used by Affymetrix Inc.